4/10
08:06 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.
Low
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.
4/5
12:01 pm
rckt
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade) [Seeking Alpha]
Low
Report
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade) [Seeking Alpha]
4/3
01:21 pm
rckt
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia [Yahoo! Finance]
Low
Report
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia [Yahoo! Finance]
4/2
02:36 pm
rckt
Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch [Seeking Alpha]
Low
Report
Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch [Seeking Alpha]
4/2
08:10 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $39.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $39.00 price target on the stock.
4/2
06:59 am
rckt
Rocket Pharma gains as EU accepts gene therapy for review [Seeking Alpha]
Medium
Report
Rocket Pharma gains as EU accepts gene therapy for review [Seeking Alpha]
4/2
06:12 am
rckt
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia [Yahoo! Finance]
Medium
Report
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia [Yahoo! Finance]
4/2
06:00 am
rckt
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Medium
Report
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
3/27
01:29 pm
rckt
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? [Yahoo! Finance]
3/26
04:07 pm
rckt
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team [Yahoo! Finance]
Low
Report
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team [Yahoo! Finance]
3/26
04:01 pm
rckt
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
Low
Report
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
3/1
06:20 pm
rckt
Rocket Pharmaceuticals' Promising Path In Gene Therapy [Seeking Alpha]
High
Report
Rocket Pharmaceuticals' Promising Path In Gene Therapy [Seeking Alpha]
3/1
12:39 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at UBS Group AG from $56.00 to $54.00. They now have a "buy" rating on the stock.
Low
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at UBS Group AG from $56.00 to $54.00. They now have a "buy" rating on the stock.
2/27
02:17 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at JPMorgan Chase & Co. from $55.00 to $50.00. They now have an "overweight" rating on the stock.
Low
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at JPMorgan Chase & Co. from $55.00 to $50.00. They now have an "overweight" rating on the stock.
2/27
02:13 pm
rckt
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 [Yahoo! Finance]
Low
Report
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 [Yahoo! Finance]
2/27
10:17 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
2/26
04:09 pm
rckt
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress [Yahoo! Finance]
Low
Report
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress [Yahoo! Finance]
2/26
04:01 pm
rckt
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
Medium
Report
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
2/13
12:21 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.
Low
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.
2/13
07:18 am
rckt
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) [Yahoo! Finance]
Medium
Report
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) [Yahoo! Finance]
2/13
07:00 am
rckt
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Medium
Report
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
2/9
10:02 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) was upgraded by analysts at StockNews.com to a "sell" rating.
1/31
01:30 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Low
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
1/30
10:11 am
rckt
Gene-Based Therapy May Slow Development of Life-Threatening Heart Condition [Yahoo! Finance]
Low
Report
Gene-Based Therapy May Slow Development of Life-Threatening Heart Condition [Yahoo! Finance]
1/22
03:45 am
rckt
Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? [Yahoo! Finance]
Medium
Report
Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? [Yahoo! Finance]